Furthermore, the findings from a study involving 112 stage III and IV patients indicated that a 75% or greater decrease in serum CA‐125 levels from primary cytoreductive surgery to the initiation of adjuvant chemotherapy served as an independent prognostic factor for progression‐free survival in patients with stage III and IV ovarian cancer [64]. Here, MUC16 is linked to ovarian cancer.